Literature DB >> 2840059

The natural history of human papillomavirus (HPV) atypia of the cervix.

R M Rome1, W Chanen, R Pagano.   

Abstract

This study examines the natural history of human papilloma virus (HPV) atypia of the cervix in 259 untreated patients who were followed for 3 to 74 months (median 18 months). Progression to cervical intraepithelial neoplasia (CIN) occurred in 41 patients (15.8%)--all but 3 progressions occurred within the first 24 months of follow-up. In no patient did invasive cancer develop during this study. Persistence occurred in 39.4% and regression in 44.8% patients. An increasing number of regressions were noted with the passage of time. Progression to histologically confirmed CIN which occurred in 23 of 46 (50%) patients in whom both the cytological and colposcopic assessment at the first visit suggested CIN did so significantly more frequently than when either the cytology or colposcopy alone suggested CIN (11 progressions in 83 patients--13.3%, p less than .00001) or when neither cytology nor colposcopy suggested CIN (7 progressions in 119 patients--5.9%, p less than .000001). We recommend that patients with both cytological and colposcopic features suggestive of CIN should be treated even though HPV atypia only is reported on biopsy. Those who are not treated should be followed closely until regression occurs and consideration should be given to treating those patients in whom the abnormality persists longer than 2 years.

Entities:  

Mesh:

Year:  1987        PMID: 2840059     DOI: 10.1111/j.1479-828x.1987.tb01010.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  2 in total

1.  Adherence to recommendations for early repeat cervical smear tests.

Authors:  H Mitchell; G Medley
Journal:  BMJ       Date:  1989-06-17

Review 2.  Vaginal drug delivery for the localised treatment of cervical cancer.

Authors:  Ian Major; Christopher McConville
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.